GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albert Labs International Corp (XCNQ:ABRT) » Definitions » Notes Receivable

Albert Labs International (XCNQ:ABRT) Notes Receivable : C$0.00 Mil (As of Sep. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Albert Labs International Notes Receivable?

Albert Labs International's Notes Receivable for the quarter that ended in Sep. 2023 was C$0.00 Mil.


Albert Labs International Notes Receivable Historical Data

The historical data trend for Albert Labs International's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albert Labs International Notes Receivable Chart

Albert Labs International Annual Data
Trend Dec21 Dec22
Notes Receivable
- -

Albert Labs International Quarterly Data
Mar21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Albert Labs International Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Albert Labs International Notes Receivable Related Terms

Thank you for viewing the detailed overview of Albert Labs International's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Albert Labs International (XCNQ:ABRT) Business Description

Traded in Other Exchanges
N/A
Address
6996, Merritt Avenue, Burnaby, BC, CAN, V5J 4R6
Albert Labs International Corp is a laboratory-based, clinical research and drug development enterprise addressing mental health care needs. The company is focusing on Real World Evidence (RWE) the company will initially look to commercialize its mycelium-based KRN-101 medicine and treatment with the help of clinical pathway.

Albert Labs International (XCNQ:ABRT) Headlines

No Headlines